=== PAGE 4 ===

COMPLETE PAGE ANALYSIS:
--------------------------------------------------
Here is the extracted text content from the PDF page, preserving its original layout and structure:

2. Collins, R., et al., Full Doses of Crenolanib, a Type I FLT3 Inhibitor, Can be Safely Administered in AML Patients Post
   Allogeneic Stem Cell Transplant. Blood, 2015. 126(23): p. 4359-4359.
3. Panetta, J.C., et al., Population Pharmacokinetics of Crenolanib, a Type I FLT3 Inhibitor, in Patients with
   Relapsed/Refractory AML. Blood, 2015. 126(23): p. 3695-3695.
4. Zhang, H., et al., Exome Sequencing Informs Mechanisms of Clinical Resistance to the FLT3-D835 Inhibitor
   Crenolanib. Blood, 2015. 126(23): p. 2468-2468.
5. Inaba, H., et al., Pilot Study of Combined Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib with Sorafenib in Pediatric
   Patients with Relapsed/Refractory FLT3+Ve AML. Blood, 2016. 128(22): p. 3937-3937.
6. Iyer, S.P., et al., Safety Study of Salvage Chemotherapy High-Dose Ara-C/Mitoxantrone (HAM) and Type I FLT3-TKI
   Crenolanib in First Relapsed/Primary Refractory AML. Blood, 2016. 128(22): p. 3983-3983.
7. Ohanian, M., et al., Efficacy of a Type I FLT3 Inhibitor, Crenolanib, with Idarubicin and High-Dose Ara-C in Multiply
   Relapsed/Refractory FLT3+ AML. Blood, 2016. 128(22): p. 2744-2744.
8. Wang, E.S., et al., Crenolanib, a Type I FLT3 TKI, can be Safely Combined with Cytarabine and Anthracycline
   Induction Chemotherapy and Results in High Response Rates in Patients with Newly Diagnosed FLT3 Mutant Acute
   Myeloid Leukemia (AML). Blood, 2016. 128(22): p. 1071-1071.
9. Cortes JE, Kantarjian HM, Kadia TM, et al. Crenolanib Besylate, a Type I Pan-FLT3 Inhibitor, to Demonstrate Clinical
   Activity in Multiply Relapsed FLT3-ITD and D835 AML. J Clin Oncol 2016; 34 (suppl; abstr 7008).
10. Stone RM, Collins R, Tallman MS, et al. Effect of Cytarabine/Anthracycline/Crenolanib Induction on Minimal Residual
    Disease (MRD) in Newly Diagnosed FLT3 Mutant AML. J Clin Oncol 2017; 35(15_suppl): 7016.
11. Wang E, Stone R, Collins R, Agrawal T, Urity V, Tallman M. Variant FLT3 Mutations Can be Eradicated by
    Cytarabine/Anthracycline/Crenolanib Induction in Adult Patients with Newly Diagnosed FLT3 (ITD/TKD) Mutant AML.
    Haematologica; 2017; 2017. p. 212.
12. Tarlock K, Hylkema T, Pollard J, et al. Functional Assessment of Novel Diagnostic FLT3 Mutations and Inhibition by
    Kinase Inhibitors. Haematologica; 2017; 2017. p. 40-1.

[Visual Element]: An image depicting a microscopic view of numerous cells, stained predominantly in shades of purple and blue, against a lighter, somewhat mottled background. The cells vary in size and shape, appearing typical of a histological or cytological preparation, possibly blood or bone marrow cells. Overlaid in white text on this image are the words: "recent peer-reviewed publications". This text serves as a header or title for the list of publications that follows, indicating their nature.

1. Wang, et al. Low Relapse Rate in Younger Patients â‰¤ 60 Years Old with Newly Diagnosed FLT3 Mutant AML Treated
   with Crenolanib and Cytarabine/Anthracycline Chemotherapy.
2. Zimmerman EI, Turner DC, Buaboonnam J, et al. Crenolanib is Active Against Models of Drug-Resistant FLT3-ITD-
   Positive Acute Myeloid Leukemia. Blood 2013; 122(22): 3607-15.
3. Fathi AT. Emergence of Crenolanib for FLT3-Mutant AML. Blood 2013; 122(22): 3547-8.
4. Smith CC, Lasater EA, Lin KC, et al. Crenolanib is a Selective Type I Pan-FLT3 Inhibitor. Proc Natl Acad Sci U S A 2014;
   111(14): 5319-24.
5. Zhang W, Gao C, Konopleva M, et al. Reversal of Acquired Drug Resistance in FLT3-Mutated Acute Myeloid Leukemia
